Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia by Paridaens, A.D.A. (Dion) et al.
doi:10.1136/bjo.85.6.658 
 2001;85;658-661 Br. J. Ophthalmol.
  
Melles 
Dion Paridaens, Houdijn Beekhuis, Willem van den Bosch, Lies Remeyer and Gerrit
  
 and primary acquired melanosis with atypia
management of conjunctival malignant melanoma 
Amniotic membrane transplantation in the
 http://bjo.bmj.com/cgi/content/full/85/6/658
Updated information and services can be found at: 
 These include:
 References
 http://bjo.bmj.com/cgi/content/full/85/6/658#otherarticles
3 online articles that cite this article can be accessed at: 
  
 http://bjo.bmj.com/cgi/content/full/85/6/658#BIBL
This article cites 8 articles, 3 of which can be accessed free at: 
Rapid responses
 http://bjo.bmj.com/cgi/eletter-submit/85/6/658
You can respond to this article at: 
  
 http://bjo.bmj.com/cgi/content/full/85/6/658#responses
2 rapid responses have been posted to this article, which you can access for free at: 
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
Topic collections
 (521 articles) Experimental Medicine 
 (1574 articles) Ophthalmology 
 (855 articles) Other Oncology 
  
Articles on similar topics can be found in the following collections 
 Notes   
 http://www.bmjjournals.com/cgi/reprintform
To order reprints of this article go to: 
 http://www.bmjjournals.com/subscriptions/
 go to: British Journal of OphthalmologyTo subscribe to 
 on 27 November 2006 bjo.bmj.comDownloaded from 
SCIENTIFIC CORRESPONDENCE
Amniotic membrane transplantation in the
management of conjunctival malignant melanoma
and primary acquired melanosis with atypia
Dion Paridaens, Houdijn Beekhuis, Willem van den Bosch, Lies Remeyer, Gerrit Melles
Abstract
Aim—To evaluate the eYcacy of amniotic
membrane transplantation (AMT) for the
management of conjunctival malignant
melanoma and primary acquired melano-
sis (PAM) with atypia.
Methods—Four consecutive patients with
histologically proved invasive, primary
conjunctival malignant melanoma were
treated with wide surgical excision and
AMT. Amniotic membrane grafts were
harvested and processed under sterile
conditions according to a standard proto-
col. The grafts were sutured to the
margins of the surface defect. In one case,
AMT was combined with a corneoscleral
graft.
Results—A satisfactory result and rapid
postoperative recovery with few, transient
side eVects was noted in three patients
with limbal/epibulbar melanomas. In
another patient with an extensive lesion,
involving the epibulbar, forniceal, and
palpebral conjunctiva, AMT following
wide excision was complicated by
symblepharon formation and restricted
ocular motility. Monitoring of local
recurrence was facilitated by the trans-
parency of the thin graft in all cases. The
postoperative follow up time varied
between several months and 3 years. In
one case, local recurrence of PAM was
observed and treated using topical mito-
mycin.
Conclusions—AMT is a useful technique
for the reconstruction of both small and
large surface defects that result from the
surgical excision of conjunctival malig-
nant melanoma and PAM. This method
facilitates wide conjunctivectomy, al-
though its role in repairing larger defects
involving the fornix or palpebral conjunc-
tiva still needs to be established. The
transparency of amniotic membrane al-
lows for monitoring of tumour recur-
rence, which is—together with superior
cosmesis—an advantage over thicker (for
example, buccal) mucous membrane
grafts.
(Br J Ophthalmol 2001;85:658–661)
The surgical management of conjunctival
malignant melanoma constitutes a clinical
challenge, especially when the tumour is large
or arises multifocally, as in primary acquired
melanosis (PAM) with atypia.1 For both condi-
tions, wide conjunctivectomy may be indi-
cated. The most radical method of eradicating
diseased conjunctiva is orbital exenteration.
This mutilating operation has been largely
abandoned as a primary procedure, as it does
not lead to increased survival in patients with
conjunctival malignant melanoma.2 Instead,
most clinicians now reserve orbital exentera-
tion to locally control advanced stages of this
neoplasm. More conservative and patient
friendly surgical techniques include the “bare
sclera” or “primary closure” methods for
smaller lesions and the use of autografts or
allografts to replace larger areas of excised con-
junctiva. Non-surgical methods to treat con-
junctival malignant melanoma and PAM in-
clude cryotherapy, radiotherapy, and topical
chemotherapy, which are now mostly used as
adjunctive tools in the management of these
neoplasms.1 3
The use of fetal membrane allografts,
including both amnion and chorion, for
ophthalmic purposes was first reported by de
Rotth in 1940.4 Recently, amniotic membrane
transplantation (AMT) was introduced by
Tseng and colleagues for the management of
patients with corneal defects, pterygia, neopla-
sia, and symblepharon.5–7 Amniotic membrane
promotes epithelialisation and inhibits fibro-
sis.8 The techniques to harvest and preserve
human amniotic membranes have been well
established.5–9 The use of this graft is consid-
ered safe, as long as the preparation is done
according to a standard protocol.5–8
Recently, a case of successful AMT was
reported in a patient with an amelanotic corneal
and limbal malignant melanoma originating
from PAM.7 This prompted us to use AMT for
surface reconstruction following wide excision
of conjunctival malignant melanomas. We re-
port on our experience with AMT in the
management of four such cases.
Patients and methods
Between 1998 and 2000, four patients with
primary conjunctival malignant melanoma
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were treated with excisional surgery and AMT
in our clinic.
PREPARATION OF AMNIOTIC MEMBRANE
The preparation of amniotic membrane was
performed according to a protocol, recently
reported elsewhere,8 which has been derived
from earlier work by Tseng et al.5–7 In brief,
amniotic membrane is obtained under sterile
conditions after elective caesarean delivery
from a HIV seronegative donor. The amniotic
membrane is separated from other placental
tissues by blunt dissection, after washing with
0.01 M phosphate buVered saline (PBS)
containing 100 mg dibekacin sulphate. The
membrane is then cut in pieces, measuring 5 ×
5 cm and rinsed three times in 0.01 M PBS.
Then it is mounted on nitrocellulose paper
with the epithelial side down and stored frozen
at −80°C until use. Preoperatively, the mem-
brane is warmed to room temperature, and
then rinsed three times in 0.01 M PBS, and in
0.01 M PBS containing 100 mg of dibekacin
sulphate.
SURGICAL TECHNIQUE OF AMNIOTIC MEMBRANE
GRAFTING
After trimming it to the appropriate size, the
amniotic membrane graft is sutured with the
epithelial side up to the corneal or conjunctival
margins of the defect using 10-0 nylon and 9-0
Vicryl respectively. Postoperatively, the patient
is fitted with a bandage lens if required, and is
treated with topical antibiotics and steroids for
several weeks.
Results
The clinical data of the four patients have been
summarised in Table 1.
In case 1, an extensive, partly elevated
malignant melanoma in the context of PAM
(and a naevus) of the temporal quadrants of
the epibulbar conjunctiva, extending onto the
limbus and temporal cornea (Fig 1(A1)) was
treated by wide excision with a free margin of 3
mm, followed by lamellar keratectomy (1.5
mm wide) and sclerectomy (4 mm wide). A
corneoscleral graft was sutured in, followed by
amniotic membrane grafting over the entire
defect (Fig 1(A3)).
As the PAM component microscopically
reached to the inferior corneal margin of resec-
tion, this area was treated with three freeze-
thaw cycles of cryotherapy followed by topical
mitomycin 0.02% three times daily for 4
weeks. After mild discomfort and transient
redness of his left eye for several weeks, the
patient recovered well and has had an excellent
cosmetic appearance (Fig 1(A2)).
In case 2, a partly pigmented elevated malig-
nant melanoma involved the medial area of
epibulbar conjunctiva, the plica, and caruncle
(Fig 1(B1)). A surrounding area of lightly pig-
mented melanosis extended to the medial part
of the superior fornix and palpebral conjunc-
tiva and downwards to the lower lid margin.
The clinically aVected conjunctiva, plica, and
caruncle were excised “en bloc” with a free
margin of 3 mm. The resulting defect was cov-
ered with two amniotic membrane grafts,
which merged at the superior fornix (Fig
1(B3)). The postoperative course was good,
with mild discomfort for the patient. In the first
weeks, during treatment with topical antibiot-
ics and steroids, there was no sign of sym-
blepharon formation. There was residual mela-
nosis at the lower lid margin and inferior
corneal limbus and conjunctiva. Four weeks
postoperatively, after tapering of the topical
steroids, a fibrotic reaction underneath the
amniotic membrane graft was noted, both near
the medial canthal area and in the superior for-
nix, leading to symblepharon and slightly
disturbed ocular motility (Fig 1(B2)). Recur-
rent PAM at the 4–5 o’clock area was treated
with topical mitomycin 0.02% three times
daily for 3 weeks.
In case 3, a limbal, amelanotic malignant
melanoma of 6 mm diameter and 2 mm eleva-
tion (Fig 1(C1)) was biopsied and later
completely excised, followed by cryotherapy of
the wound bed (Fig 1(C3)). The defect was
covered with an amniotic membrane graft.
During the follow up period of more than 2
years, a pterygium-like reaction was observed
at the transplanted area, with fibrosis and
hyperaemia (Fig 1(C2)), causing slight
astigmatism, but no signs of tumour recur-
rence.
In case 4, a nodular malignant melanoma at
the temporal limbus with a diameter of 6 mm
Table 1 Clinical findings and outcome of four patients with conjunctival melanoma following wide excision and amniotic membrane transplantation
Case No, age
at time of
diagnosis, sex Precursor
Location of
conjunctival
melanoma
(and PAM)
Breslow
thickness
(mm)
Primary
treatment
Completely
resected
Secondary
treatment
Follow up
(months)
Cosmetic
outcome
Signs of
recurrence at
end follow up
Fibrotic
reaction/symblepharonMM* PAM†
1; 49; M PAM +
naevus
corneolimbal;
epibulbar
2.6 wide excision +
corneoscleral
graft + AMT‡
yes no Cryotherapy;
topical
mitomycin 0.02%
16 excellent no —
2; 70; F PAM limbal; epibulbar;
plica; caruncle;
forniceal; palpebral
2.1 wide excision
+ AMT
yes no Topical
mitomycin 0.02%
16 moderate yes (PAM) ++
3; 54; M de novo corneolimbal;
epibulbar
2.7 wide excision
+ cryotherapy
+ corneoscleral
graft + AMT
yes — — 28 good no +
4; 64; M naevus limbal; epibulbar 1.6 wide excision
+ AMT
yes — — 5 excellent no —
*MM = malignant melanoma.
†PAM = primary acquired melanosis.
‡AMT = amniotic membrane transplantation.
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Figure 1 (A1) Preoperative view of a nodular, deeply pigmented conjunctival malignant melanoma arising in the context of primary acquired melanosis
and a naevus in the temporal (epibulbar) quadrants of the left eye in a 49 year old man (case 1). (A2) Excellent cosmetic and functional result at 8 weeks
after conjunctival and corneoscleral excisional surgery, corneoscleral grafting combined with amniotic membrane grafting (AMT), followed by cryotherapy
and a topical mitomycin course (case 1). (A3) Schematic drawing depicting the areas of conjunctival and corneoscleral resection in case 1. (B1)
Preoperative view of an irregular, partly pigmented elevated malignant melanoma involving the medial area of epibulbar conjunctiva, the plica, and the
caruncle of the right eye in a 70 year old woman. The tumour originates from flat, lightly pigmented melanosis, extending into the medial part of the
superior and inferior fornix and palpebral conjunctiva, and the lower lid margin (case 2). (B2) At 3 weeks after excisional surgery and AMT,while the
patient was still using topical steroids, there was no sign of symblepharon formation. In the following weeks, when the steroids were tapered down, a fibrotic
reaction underneath the amniotic membrane was noted (case 2). (B3) Schematic drawing depicting the areas of excised conjunctiva in case 2. (C1)
Preoperative view of a nodular, amelanotic malignant melanoma at the limbus of the right eye in a 54 year old Asian man (case 3). (C2) No sign of local
recurrence at 2 years following excisional surgery, cryotherapy, and AMT.Note the pterygium-like reaction of the transplanted area, with mild fibrosis and
hyperaemia (case 3). (C3) Schematic drawing depicting the areas of corneoscleral and conjunctival resection in case 3. (D1) Preoperative view of a
nodular, darkly pigmented, limbal malignant melanoma of the left eye in a 64 year old man (case 4). (D2) Satisfactory cosmetic and functional result at 4
weeks following tumour excision and AMT.The oedema and hyperaemia of the graft area is subsiding (case 4). (D3) Schematic drawing depicting the
areas of conjunctival resection in case 4.
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(Fig 1(D1)), which had originated from a pre-
existing naevus, was excised with clinically free
margins of 3 mm. The defect was closed with
an amniotic membrane graft (Fig 1(D3)). In
the postoperative phase, the graft exhibited
epithelial overgrowth, and transient oedema
and hyperaemia (Fig 1(D2)).
Discussion
These four cases demonstrate the successful
use of AMT for the reconstruction of ocular
surface defects following surgical excision of
conjunctival malignant melanoma and PAM.
The advantages of this new technique for
this indication include: (1) the cosmetic
appearance following surgery, (2) the absence
of donor site morbidity complicating the
harvest of mucosal autografts, and (3) the abil-
ity to clinically monitor local recurrence of
tumour underneath the transparent amniotic
membrane graft. Furthermore, for more ad-
vanced cases, in which there is extensive,
superficial conjunctival involvement, this tech-
nique may preclude or at least postpone a
mutilating orbital exenteration.2
AMT caused short term mild ocular dis-
comfort and redness due to oedema and
hyperaemia, which responded well to topical
steroids and antibiotics. In the longer term,
symblepharon formation and restricted ocular
motility were noted in one case (no 2), in
which the extensive tumour involved both the
epibulbar, the forniceal, and the palpebral con-
junctiva and the caruncle. In this case, two
amniotic membrane grafts were sutured into
the defects of, respectively, the epibulbar and
palpebral conjunctiva. We speculate that a con-
tinuous layer of amniotic membrane, stretch-
ing from the epibulbar area via the fornix to the
anterior margin of the upper lid might have
caused less symblepharon formation. Further-
more, the patient in case 3 developed a mild
pterygium-like fibrotic reaction, while in case 4
the follow up time has been too short to evalu-
ate this complication.
In the four cases, alternative methods to
cover the conjunctival surface defects, includ-
ing conjunctival or other mucosal autografts,
could have been used. The defects were
considered to be too large for primary closure
or leaving the sclera uncovered (bare sclera
technique). The use of conjunctival autografts
was also regarded as unappealing, since the
harvest of these grafts may inflict serious donor
site morbidity, including symblepharon or
restricted ocular or eyelid motility. Further-
more, patients may refuse to have an operation
on their unaVected eye for donor purposes. In
a recent comparative study between the use of
conjunctival autografts, amniotic membrane
grafts, and primary closure in the management
of pterygia, the investigators felt that, despite
the better results following the use of conjunc-
tival autografts, AMT may be considered as an
alternative first choice treatment.6 The use of
thicker mucosal grafts—for example, buccal or
inner lip, has cosmetic disadvantages com-
pared with AMT, especially when visible areas
of (epibulbar) conjunctiva are involved. Also,
these thicker grafts may mask tumour growth
underneath for a long time.2
We conclude that AMT is a promising tech-
nique in the treatment of the large ocular
surface defects resulting from the radical exci-
sion of malignant melanoma and PAM. It
facilitates extensive conjunctivectomy, which is
required for larger or diVuse “multicentric”
melanoma or melanosis, especially when the
tumour is amelanotic.10 In our study with a fol-
low up of several months up to 3 years, AMT
was complicated by mild symblepharon and
fibrosis in two of four cases. Our cases as well
as the case reported by Tseng et al7 suggest that
the best results of AMT are likely to occur in
patients with limbal or epibulbar melanomas.
Further study into the prevention of sym-
blepharon complicating AMT is needed to
increase the functional and cosmetic outcome
of treated patients.
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